<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3633896c-95f9-f86b-e063-6294a90aad7c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">
         <content styleCode="bold">These highlights do not include all the information needed to use PYRUKYND safely and effectively. See full prescribing information for PYRUKYND.</content>
      </content>
      <br/>
      <br/>
      <content styleCode="bold">
         <content styleCode="bold">
            <content styleCode="bold">PYRUKYND 
    <sup>Â®</sup>(mitapivat) tablets, for oral use
    <br/>
Initial U.S. Approval: 2022 
   </content>
         </content>
      </content>
   </title>
   <effectiveTime value="20250528"/>
   <setId root="4ccee896-e313-4c6c-9674-b4746ada0a90"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="011567735"/>
            <name>Agios Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3633c632-59ed-4702-e063-6294a90afae6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250528"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71334-210" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYRUKYND</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mitapivat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MITAPIVAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71334-210-14" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="4" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-210-20" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220218"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M20</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71334-205" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYRUKYND</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mitapivat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MITAPIVAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71334-205-14" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="4" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-205-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220218"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M5</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="5" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71334-215" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYRUKYND</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mitapivat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MITAPIVAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71334-215-14" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="4" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-215-50" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220218"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M50</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71334-220" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYRUKYND</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mitapivat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MITAPIVAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-220-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220218"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M5</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="5" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71334-225" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYRUKYND</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mitapivat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71334-225-12" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="71334-210" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>PYRUKYND</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mitapivat</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 2</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIACETIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="20"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>MITAPIVAT</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="7" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-210-07" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">M20</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="8" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="71334-205" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>PYRUKYND</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mitapivat</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 2</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIACETIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="5"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>MITAPIVAT</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="7" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-205-07" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">M5</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="5" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71334-230" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYRUKYND</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mitapivat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71334-230-13" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="71334-215" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>PYRUKYND</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mitapivat</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 2</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIACETIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="50"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>MITAPIVAT</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="7" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-215-07" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">M50</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="16" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="71334-210" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>PYRUKYND</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mitapivat</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 2</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIACETIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="20"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MITAPIVAT</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="2WTV10SIKH" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>MITAPIVAT</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="7" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71334-210-07" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">M20</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                                    <originalText/>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="8" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216196" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220218"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_e5127dd0-e971-4ddf-ac5a-e1d024e9d7db">
               <id root="3633492b-60e8-f316-e063-6394a90a21d1"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text>
                  <paragraph>Warnings and Precautions, Hepatocellular Injury in Another Condition (5.2)Â Â Â  Â Â Â Â  01/2025</paragraph>
               </text>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions, Hepatocellular Injury in Another Condition (
 
    <linkHtml href="#LINK_bd3c824d-ed74-4150-83c5-482dac1c8ed4">5.2</linkHtml>)Â Â Â  Â Â Â Â  01/2025

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_9cedbd71-478e-49e9-8e01-1d453a8ab86a">
               <id root="3633492b-60e9-f316-e063-6394a90a21d1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.</paragraph>
               </text>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. (
 
    <linkHtml href="#LINK_9cedbd71-478e-49e9-8e01-1d453a8ab86a">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8f555a37-6936-42bd-a5b5-8da119928076">
               <id root="3633492b-60ea-f316-e063-6394a90a21d1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>PYRUKYND is taken orally with or without food. The tablets should be swallowed whole. Do not split, crush, chew, or dissolve the tablets.</paragraph>
               </text>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Starting dosage: 5 mg orally twice daily with or without food. (
  
     <linkHtml href="#LINK_45f53ca3-7bd3-45f9-9968-5087209b2d8f">2.1</linkHtml>)
 
    </item>
                           <item>See Full Prescribing Information for dose titration and taper schedule. (
  
     <linkHtml href="#LINK_45f53ca3-7bd3-45f9-9968-5087209b2d8f">2.1</linkHtml>,
  
     <linkHtml href="#LINK_9851fdc9-9070-443d-8c07-6440fdbbd973">2.3</linkHtml>)
 
    </item>
                           <item>The tablet should be swallowed whole. (
  
     <linkHtml href="#LINK_45f53ca3-7bd3-45f9-9968-5087209b2d8f">2.1</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_45f53ca3-7bd3-45f9-9968-5087209b2d8f">
                     <id root="3633492b-60eb-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dose</title>
                     <text>
                        <paragraph>PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew, or dissolve the tablets.</paragraph>
                        <paragraph>The starting dosage for PYRUKYND is 5 mg orally twice daily. To gradually increase hemoglobin (Hb), titrate PYRUKYND from 5 mg twice daily to 20 mg twice daily, and then to the maximum recommended dose of 50 mg twice daily, with these dose increases occurring every 4 weeks (see Table 1). Assess Hb and transfusion requirement before increasing to the next dose level, as some patients may reach and maintain normal Hb at 5 mg twice daily or 20 mg twice daily.</paragraph>
                        <paragraph>Discontinue PYRUKYND if no benefit has been observed by 24 weeks, based on the hemoglobin and hemolysis laboratory results and transfusion requirements.</paragraph>
                        <table width="658px">
                           <caption>Table 1: Dose Titration Schedule</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Duration</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Dosage</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Week 1 through Week 4</td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">5 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Week 5 through Week 8</td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>If Hb is below normal range or patient has required a transfusion within the last 8 weeks:</paragraph>
                                    <list listType="unordered">
                                       <item>Increase to 20 mg twice daily and maintain for 4 weeks. If Hb is within normal range and patient has not required a transfusion within the last 8 weeks:</item>
                                       <item>Maintain 5 mg twice daily.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Week 9 through Week 12</td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>If Hb is below normal range or patient has required a transfusion within the last 8 weeks:</paragraph>
                                    <list listType="unordered">
                                       <item>Increase to 50 mg twice daily and maintain thereafter. If Hb is within normal range and patient has not required a transfusion within the last 8 weeks:</item>
                                       <item>Maintain current dose (5 mg twice daily or 20 mg twice daily).</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â Maintenance</td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">If Hb decreases, consider up-titration to the maximum of 50 mg twice daily as per the above schedule.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f0286713-ea2c-4d9d-9dc9-f75bb2eb193a">
                     <id root="3633492b-60ec-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Missed Dose</title>
                     <text>
                        <paragraph>If a dose of PYRUKYND is missed by 4 hours or less, administer the dose as soon as possible. If a dose of PYRUKYND is missed by more than 4 hours, do not administer a replacement dose, and wait until the next scheduled dose. Subsequently, return to the normal dosing schedule.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9851fdc9-9070-443d-8c07-6440fdbbd973">
                     <id root="3633492b-60ed-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Interruption or Discontinuation</title>
                     <text>
                        <paragraph>To reduce the risk of acute hemolysis, avoid abrupt interruption or abrupt discontinuation of PYRUKYND when possible
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_a4c74e6f-f2ba-4af6-b6f2-2764e2a7c13f">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>. Taper the dose to gradually discontinue the medication (see Table 2). Monitor patients for signs of acute hemolysis and worsening of anemia.

 </paragraph>
                        <table width="618px">
                           <caption>Table 2 Dose Taper Schedule</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Current Dose</content>
                                 </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Dose Taper Schedule</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Day 1-7</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Day 8-14</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Day 15</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 5 mg twice daily</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 5 mg
    
     <content styleCode="bold">once</content>daily
   
    </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â Discontinue</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â N/A</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 20 mg twice daily</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 20 mg
    
     <content styleCode="bold">once</content>daily
   
    </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 5 mg
    
     <content styleCode="bold">once</content>daily
   
    </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â Discontinue</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 50 mg twice daily</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 50 mg
    
     <content styleCode="bold">once</content>daily
   
    </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 20 mg
    
     <content styleCode="bold">once</content>daily
   
    </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â Discontinue</td>
                              </tr>
                              <tr>
                                 <td colspan="4">Â Abbreviations: N/A = not applicable.</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ead6df25-3aed-4ed8-bfa4-4d55e3cb654e">
                     <id root="3633492b-60ee-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage for Hepatic Impairment</title>
                     <text>
                        <paragraph>Avoid use of PYRUKYND in patients with moderate or severe hepatic impairment
 
  <content styleCode="italics">
                              <content styleCode="italics">[see
   
    <linkHtml href="#LINK_a1d528f0-49b9-4fea-8315-0e5bf07ba5ea">Use in Special Populations (8.6)</linkHtml>Â and
   
    <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>].
  
   </content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e932bbe4-b41f-4fce-b5c7-699cdbbd567b">
                     <id root="3633492b-60ef-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5Â Recommended Dosage for Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Strong CYP3A Inhibitors</content>
                        </paragraph>
                        <paragraph>Avoid co-administration of strong CYP3A inhibitors with PYRUKYND
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">Drug Interactions (7.1)</linkHtml>Â and
  
   <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Moderate CYP3A Inhibitors</content>
                        </paragraph>
                        <paragraph>Monitor Hb and for increased risks of adverse reactions from PYRUKYND. When used with a moderate CYP3A inhibitor, do not titrate PYRUKYND beyond 20 mg twice daily
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">Drug Interactions (7.1)</linkHtml>Â and
  
   <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Strong CYP3A Inducers</content>
                        </paragraph>
                        <paragraph>Avoid co-administration of strong CYP3A inducers with PYRUKYND
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">Drug Interactions (7.1)</linkHtml>Â and
  
   <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Moderate CYP3A Inducers</content>
                        </paragraph>
                        <paragraph>Consider alternative therapies that are not moderate CYP3A inducers during treatment with PYRUKYND. If there are no alternative therapies, monitor Hb and titrate beyond the 50 mg twice daily dose, if necessary, but do not exceed a maximum recommended dose of 100 mg twice daily
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">Drug Interactions (7.1)</linkHtml>Â and
  
   <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5d4801bd-622d-4373-8e55-5e4b8a348e59">
                     <id root="3633492b-60f0-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6Â Dose Modifications for Adverse Reactions and Hemoglobin Levels Above Normal</title>
                     <text>
                        <paragraph>If a dose reduction is required because of an adverse reaction or tolerability, or for Hb above normal, the dose may be reduced to the next lower dose level, 20 mg twice daily or 5 mg twice daily.</paragraph>
                        <paragraph>If a patient needs to discontinue PYRUKYND, the dose taper schedule (Table 2) should be followed. In situations where the risk to the patient due to the adverse reaction or Hb above normal is greater than the risk of acute hemolysis due to sudden withdrawal of the drug, treatment may be stopped without taper and patients should be monitored for signs of acute hemolysis.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2e960009-a611-4801-81a9-0a06a0dd5060">
               <id root="3633492b-60f1-f316-e063-6394a90a21d1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered">
                     <item>5 mg tablets: round, blue, film-coated tablets with "M5" printed on one side.</item>
                     <item>20 mg tablets: round, blue, film-coated tablets with "M20" printed on one side.</item>
                     <item>50 mg tablets: oblong, blue, film-coated tablets with "M50" printed on one side.</item>
                  </list>
               </text>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 5 mg, 20 mg, and 50 mg. (
 
    <linkHtml href="#LINK_2e960009-a611-4801-81a9-0a06a0dd5060">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_bccf7bac-de59-4df1-a636-4a1c4f326ecc">
               <id root="3633492b-60f2-f316-e063-6394a90a21d1"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (
 
    <linkHtml href="#LINK_bccf7bac-de59-4df1-a636-4a1c4f326ecc">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_15a36c96-7ef1-49f2-b7ff-0df21df744ab">
               <id root="3633492b-60f3-f316-e063-6394a90a21d1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Acute Hemolysis: Avoid abrupt interruption or abrupt discontinuation of PYRUKYND to minimize the risk of acute hemolysis. A gradual reduction in dosing rather than abrupt cessation is recommended when possible. (
  
     <linkHtml href="#LINK_a4c74e6f-f2ba-4af6-b6f2-2764e2a7c13f">5.1</linkHtml>)
 
    </item>
                           <item>Hepatocellular Injury in Another Condition: Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is &gt;5 times the upper limit of normal (ULN). Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected. (
  
     <linkHtml href="#LINK_bd3c824d-ed74-4150-83c5-482dac1c8ed4">5.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_a4c74e6f-f2ba-4af6-b6f2-2764e2a7c13f">
                     <id root="3633492b-60f4-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Acute Hemolysis with Abrupt Treatment Interruption</title>
                     <text>
                        <paragraph>Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#LINK_9851fdc9-9070-443d-8c07-6440fdbbd973">2.3</linkHtml>,
  
   <linkHtml href="#LINK_5d4801bd-622d-4373-8e55-5e4b8a348e59">2.6</linkHtml>)]
 
  </content>. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath
 
  <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_bd3c824d-ed74-4150-83c5-482dac1c8ed4">
                     <id root="3633492b-60f5-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2Â Hepatocellular Injury in Another Condition</title>
                     <text>
                        <paragraph>In patients with another condition treated with PYRUKYND at a higher dose than that recommended for patients with PK deficiency, liver injury has been observed. These events were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of &gt;5ÃULN with or without jaundice. All patients discontinued treatment with PYRUKYND, and these events improved upon treatment discontinuation.</paragraph>
                        <paragraph>Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is &gt;5 times the upper limit of normal (ULN). Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_611ede15-caab-4861-9721-cb1111fd39d2">
               <id root="3633492b-60f6-f316-e063-6394a90a21d1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reaction is described elsewhere in labeling:</paragraph>
                  <list listType="unordered">
                     <item>Acute Hemolysis with Abrupt Treatment Discontinuation
  
   <content styleCode="italics">[see
   
    <content styleCode="italics">
                              <linkHtml href="#LINK_a4c74e6f-f2ba-4af6-b6f2-2764e2a7c13f">Warn</linkHtml>
                           </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_a4c74e6f-f2ba-4af6-b6f2-2764e2a7c13f">ings and Preca</linkHtml>
                           </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_a4c74e6f-f2ba-4af6-b6f2-2764e2a7c13f">utions (5.1)</linkHtml>
                           </content>].
  
   </content>
                     </item>
                     <item>Hepatocellular Injury in Another Condition
  
   <content styleCode="italics">[see
   
    <linkHtml href="#LINK_bd3c824d-ed74-4150-83c5-482dac1c8ed4">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>.
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions including laboratory abnormalities (â¥ 10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia. (
 
    <linkHtml href="#LINK_9e219b91-d169-423f-9636-16af5d1c09bc">6.1</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="bold">
                                 <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Agios Pharmaceuticals at 1-833-228-8474 or FDA at 1-800-FDA-1088 or</content>
                                 <content styleCode="bold">www.fda.gov/medwatch.</content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9e219b91-d169-423f-9636-16af5d1c09bc">
                     <id root="3633492b-60f7-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>A total of 155 patients received PYRUKYND, 79% of whom were exposed for longer than 24 weeks. PYRUKYND was administered up to 50 mg orally twice daily in 67 patients with PK deficiency in the ACTIVATE trial (N=40) and the ACTIVATE-T trial (N=27)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_3b95ac3a-e22f-442a-b814-8f94b19716d2">Clinical Studies (14)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">ACTIVATE Trial</content>
                        </paragraph>
                        <paragraph>In the ACTIVATE trial patients with PK deficiency who were not regularly transfused received PYRUKYND in incremental doses up to 50 mg twice daily (N=40) or placebo (N=39).</paragraph>
                        <paragraph>Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE Trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, which each occurred in 1 patient.</paragraph>
                        <paragraph>In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (â¥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.</paragraph>
                        <paragraph>Table 3 summarizes the adverse reactions in the ACTIVATE trial.</paragraph>
                        <table width="603px">
                           <caption>Table 3: Adverse Reactions (â¥ 5%) in Patients Receiving PYRUKYND in ACTIVATE</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">PYRUKYND</content>
                                    </paragraph>
                                    <content styleCode="bold">(N=40)</content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <content styleCode="bold">
                                       <content styleCode="bold">(N=39)</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="bold">(%)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <paragraph>
                                       <content styleCode="bold">Grade â¥3</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="bold">(%)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="bold">(%)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Grade â¥3</content>
                                    </paragraph>
                                    <content styleCode="bold">(%)</content>Â 
   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Back pain
    
     <sup>a</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">15%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Arthralgia
    
     <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">10%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypertriglyceridemia
    
     <sup>c</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">3%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Gastroenteritis</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 8%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 3%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hot flush
    
     <sup>d</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 8%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Oropharyngeal pain</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Hypertension</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Arrhythmia
    
     <sup>e</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Breast discomfort</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Constipation</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Dry mouth
    
     <sup>f</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Paresthesia</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">0Â </td>
                              </tr>
                              <tr>
                                 <td colspan="5">
                                    <paragraph>Grades: Per the CTCAE definition.</paragraph>
                                    <paragraph>
                                       <content styleCode="underline">Grouped Term Definitions</content>
                                    </paragraph>
                                    <paragraph>
                                       <sup>a</sup>Includes back pain, sciatica, and flank pain.
    
     </paragraph>
                                    <paragraph>
                                       <sup>b</sup>Includes arthralgia and joint swelling.
    
     </paragraph>
                                    <paragraph>
                                       <sup>c</sup>Includes hypertriglyceridemia and blood triglycerides increased.
    
     </paragraph>
                                    <paragraph>
                                       <sup>d</sup>Includes hot flush and flushing.
    
     </paragraph>
                                    <paragraph>
                                       <sup>e</sup>Includes arrhythmia, tachycardia, heart rate increased and atrial fibrillation.
    
     </paragraph>
                                    <sup>fÂ Â </sup>Includes dry mouth and dry lip.
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Laboratory abnormalities of PYRUKYND included increased urate (15%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Variations in Reproductive Hormones</content>
                        </paragraph>
                        <paragraph>In ACTIVATE, increases in serum testosterone and decreases in serum estrone and estradiol were observed in men receiving PYRUKYND (Table 4). These changes in hormones persisted throughout the study period. In patients who discontinued PYRUKYND and had follow-up hormone measurements, the hormone changes returned close to the baseline levels 28 days after discontinuing PYRUKYND. In female patients, sex hormone analysis was limited due to physiologic variations in hormones during the menstrual cycle and the use of hormonal contraceptives.</paragraph>
                        <table width="599px">
                           <caption>Table 4: Laboratory Abnormalities in Reproductive Hormones in Men Receiving PYRUKYND</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">ACTIVATE</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Parameter</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">PYRUKYND 
       <br/>
                                       </content>
                                       <content styleCode="bold">(16 males) 
       <br/>
                                       </content>
                                       <content styleCode="bold">
                                          <content styleCode="bold">n (%)</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo 
       <br/>
                                       </content>
                                       <content styleCode="bold">
                                          <content styleCode="bold">(15 males)n 
        <br/>  (%)
       </content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="italics">
                                          <content styleCode="bold">
                                             <content styleCode="italics">Reproductive hormone analyses
        
         <sup>a</sup>
                                             </content>
                                          </content>
                                       </content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Estrone decreased (males) 
      <br/>  Estradiol decreased (males) 
      <br/>  Blood testosterone increased (males)
     </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9 (56.3) 
      <br/>  2 (12.5) 
      <br/>  1 (6.3)
     </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0 
      <br/>  1 (6.7) 
      <br/>  1 (6.7)
     </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3">
                                    <sup>aÂ </sup>Decreases in estrone and estradiol to below the lower limit of the reference range and increases in testosterone to above the upper limit of the reference range where baseline was within normal limits.
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Â </content>
                           <content styleCode="italics">ACTIVATE-T Trial</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Â </content>The adverse reactions reported in the population of patients who were regularly transfused (ACTIVATE-T) were consistent with that seen in ACTIVATE.

 </paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5984e014-3642-4eda-ad9f-4222d98a149c">
               <id root="3633492b-60f8-f316-e063-6394a90a21d1"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Strong CYP3A Inhibitors and Inducers: Avoid concomitant use. (
  
     <linkHtml href="#LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">7.1</linkHtml>)
 
    </item>
                           <item>Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily. (
  
     <linkHtml href="#LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">7.1</linkHtml>)
 
    </item>
                           <item>Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage. (
  
     <linkHtml href="#LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">7.1</linkHtml>)
 
    </item>
                           <item>Sensitive CYP3A, CYP2B6, CYP2C substrates including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index. (
  
     <linkHtml href="#LINK_a0af40e9-1587-4f29-93a1-8a6c3d8f8145">7.2</linkHtml>)
 
    </item>
                           <item>UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index. (
  
     <linkHtml href="#LINK_a0af40e9-1587-4f29-93a1-8a6c3d8f8145">7.2</linkHtml>)
 
    </item>
                           <item>P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index. (
  
     <linkHtml href="#LINK_a0af40e9-1587-4f29-93a1-8a6c3d8f8145">7.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_cedaa087-a3e7-47e9-a9cb-b17f85026eb6">
                     <id root="3633492b-60f9-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1Â Effect of Other Drugs on PYRUKYND</title>
                     <text>
                        <table width="594px">
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Strong CYP3A Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Co-administration of PYRUKYND with strong CYP3A inhibitors increased mitapivat plasma concentrations
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                       <item>Increased mitapivat plasma concentrations may increase the risks of adverse reactions of PYRUKYND.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Avoid co-administration of strong CYP3A inhibitors with PYRUKYND
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_e932bbe4-b41f-4fce-b5c7-699cdbbd567b">Dosage and Administration (2.5)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Moderate CYP3A Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Co-administration of PYRUKYND with moderate CYP3A inhibitors will increase mitapivat plasma concentrations
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Monitor Hb and for increased risks of adverse reactions with PYRUKYND.</item>
                                       <item>Do not titrate PYRUKYND beyond 20 mg twice daily
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_e932bbe4-b41f-4fce-b5c7-699cdbbd567b">Dosage and Administration (2.5)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Strong CYP3A Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Co-administration of PYRUKYND with strong CYP3A inducers decreased mitapivat plasma concentrations
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                       <item>Decreased mitapivat plasma concentrations will reduce the efficacy of PYRUKYND.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Avoid co-administration of strong CYP3A inducers with PYRUKYND
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_e932bbe4-b41f-4fce-b5c7-699cdbbd567b">Dosage and Administration (2.5)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Moderate CYP3A Inducers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Co-administration of PYRUKYND with moderate CYP3A inducers will decrease mitapivat plasma concentrations
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Consider alternative therapies that are not moderate CYP3A inducers during treatment with PYRUKYND. If there are no alternative therapies, monitor Hb and titrate beyond 50 mg twice daily, if necessary, but do not exceed a maximum recommended dose of 100 mg twice daily
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_e932bbe4-b41f-4fce-b5c7-699cdbbd567b">Dosage and Administration (2.5)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a0af40e9-1587-4f29-93a1-8a6c3d8f8145">
                     <id root="3633492b-60fa-f316-e063-6394a90a21d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2Â Effect of PYRUKYND on Other Drugs</title>
                     <text>
                        <table width="520px">
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">CYP3A Substrates</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>PYRUKYND induces CYP3A. Co-administration of PYRUKYND will decrease systemic concentrations of drugs that are sensitive CYP3A substrates, including hormonal contraceptives (e.g., ethinyl estradiol)
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <list listType="unordered">
                                       <item>Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic index when co- administered with PYRUKYND.</item>
                                       <item>Advise patients using hormonal contraceptives to use an alternative non-hormonal contraceptive method or add a barrier method of contraception during treatment with PYRUKYND.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">CYP2B6 and CYP2C Substrates</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>PYRUKYND induces CYP2B6, CYP2C8, CYP2C9, and CYP2C19 enzymes
      
       <content styleCode="italics">in vitro</content>, and may decrease systemic concentrations of drugs that are sensitive substrates of these enzymes
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Monitor patients for loss of therapeutic effect of sensitive substrates of these enzymes with narrow therapeutic index when co-administered with PYRUKYND.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">UGT1A1 Substrates</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>PYRUKYND induces UGT1A1
      
       <content styleCode="italics">in vitro</content>and may decrease systemic concentrations of drugs that are UGT1A1 substrates
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Monitor patients for loss of therapeutic effect of UGT1A1 substrates with narrow therapeutic index when co-administered with PYRUKYND.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">P-gp Substrates</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clinical Impact</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>PYRUKYND inhibits the P-gp transporter
      
       <content styleCode="italics">in vitro</content>and may increase systemic concentrations of drugs that are P-gp substrates
      
       <content styleCode="italics">[see
       
        <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>]
      
       </content>.
     
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Prevention or Management</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <list listType="unordered">
                                       <item>Monitor patients for adverse reactions of P-gp substrates with narrow therapeutic index when co-administered with PYRUKYND.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cb485e42-9e19-431f-832f-5ebb0e94ee6c">
               <id root="3633492b-60fb-f316-e063-6394a90a21d1"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250109"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate or Â severe hepatic impairment. (
 
    <linkHtml href="#LINK_a1d528f0-49b9-4fea-8315-0e5bf07ba5ea">8.6</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_698fa7db-1fef-42e4-b687-95e98986857b">
                     <id root="3633492b-60fc-f316-e063-6394a90a21d1"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from clinical trials of PYRUKYND are insufficient to evaluate for a drug- associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.</paragraph>
                        <paragraph>In animal reproduction studies, mitapivat orally administered twice daily to pregnant rats and rabbits during organogenesis was not teratogenic at doses up to 13 and 3 times the maximum recommended human dose (MRHD) of 50 mg twice daily, respectively. Mitapivat administered orally to pregnant rats twice daily during organogenesis through lactation did not result in adverse developmental effects at doses up to 13 times the MRHD (
 
  <content styleCode="italics">see Data</content>).

 </paragraph>
                        <paragraph>The estimated background risk of major birth defects for the indicated population is unknown. Estimated frequencies for other important background risks in the population are as follows: miscarriage 18%, growth retardation 24%, preterm birth 56%. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Disease-Associated Maternal Risk</content>
                           </content>
                        </paragraph>
                        <paragraph>Untreated PK deficiency in pregnant women may precipitate acute hemolysis, pre-term labor, miscarriage and severe anemia requiring frequent transfusion. Additionally, preeclampsia and severe hypertension have been reported.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Animal Data</content>
                           </content>
                        </paragraph>
                        <paragraph>In an embryo-fetal development study in rats, mitapivat was administered at doses of 5, 10, 25, and 100 mg/kg twice daily by oral gavage during the period of organogenesis (gestation days 6 to 17). There was a statistically significant 14% decrease in maternal net body weight gain at the high dose with associated decrease in food consumption. Enlarged or fused placenta and/or a distended amniotic sac, an increase in post-implantation loss (early and late resorptions), a decrease in the mean number of viable fetuses, lower mean fetal weights, and external, visceral, and skeletal malformations were observed at the high dose (100 mg/kg twice daily, 63 times the MRHD, based on area under the plasma drug concentration-time curve [AUC]). No maternal or embryo-fetal toxicity was observed up to 25 mg/kg twice daily (13 times the MRHD, based on AUC).</paragraph>
                        <paragraph>In an embryo-fetal development study in rabbits, mitapivat was administered at doses of 12.5, 30, and 62.5 mg/kg twice daily by oral gavage during the period of organogenesis (gestation days 7 to 20). Lower fetal weight was observed at 62.5 mg/kg twice daily (3 times MRHD, based on AUC) and correlated with reduced maternal body weight gain. No effects on fetal morphology were observed.</paragraph>
                        <paragraph>In a pre- and post-natal development study in rats, mitapivat was administered at doses of 5, 10, 25, and 100 mg/kg twice daily by oral gavage during the period of organogenesis and continuing to weaning (gestation day 7 to lactation day 20). Dystocia was observed at â¥25 mg/kg twice daily (â¥13x MRHD, based on AUC). At 100 mg/kg twice daily (63x MRHD, based on AUC) decreased maternal body weight gain, prolonged parturition, and dystocia occurred and resulted in maternal mortality, complete litter loss, decreased pup viability and decreased pup body weight. No adverse effects on pup growth and development, and reproductive performance were observed up to 50 mg/kg (13 times the MRHD, based on AUC).</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1487aa70-63cf-417d-8947-1c5412873da2">
                     <id root="3633492b-60fd-f316-e063-6394a90a21d1"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of PYRUKYND or its metabolites in human or animal milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for PYRUKYND and any potential adverse effects on the breastfed child from PYRUKYND or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f2797901-ab74-4759-9bdc-152500329adf">
                     <id root="3633492b-60fe-f316-e063-6394a90a21d1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_261c6100-e7b3-40b7-85bf-f5f473dae1ba">
                     <id root="3633492b-60ff-f316-e063-6394a90a21d1"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of PYRUKYND did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a1d528f0-49b9-4fea-8315-0e5bf07ba5ea">
                     <id root="3633492b-6100-f316-e063-6394a90a21d1"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Mitapivat undergoes extensive hepatic metabolism. Moderate and severe hepatic impairment is expected to increase the systemic exposure of mitapivat. Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_ead6df25-3aed-4ed8-bfa4-4d55e3cb654e">Dosage and Administration (2.4)</linkHtml>,
  
   <linkHtml href="#LINK_bd3c824d-ed74-4150-83c5-482dac1c8ed4">Warnings and Precautions (5.2)</linkHtml>, and
  
   <linkHtml href="#LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_88ed48cc-536d-494e-bcc6-0bf5935ec7c1">
               <id root="3633492b-6101-f316-e063-6394a90a21d1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>The active ingredient of PYRUKYND is mitapivat, a pyruvate kinase activator, present as mitapivat sulfate. The chemical name of mitapivat sulfate is 8-quinolinesulfonamide, N-[4-[[4- (cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-, sulfate, hydrate (2:1:3). The chemical structure of mitapivat sulfate is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>The molecular formula is (C
 
  <sub>24</sub>H
 
  <sub>26</sub>N
 
  <sub>4</sub>SO
 
  <sub>3</sub>)
 
  <sub>2</sub>â¢ H
 
  <sub>2</sub>SO
 
  <sub>4</sub>â¢ 3H
 
  <sub>2</sub>O, and the molecular weight is 1053.23 for mitapivat sulfate. Mitapivat sulfate is a white to off-white solid and is slightly soluble in water.

 </paragraph>
                  <paragraph>PYRUKYND is available as 5 mg, 20 mg, and 50 mg tablets for oral administration. Each tablet contains 5 mg, 20 mg, or 50 mg mitapivat free base, provided as 5.85 mg, 23.4 mg, or 58.5 mg, respectively, of the sulfate hydrate salt, and the following inactive ingredients: croscarmellose sodium, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. The tablet film coating contains the inactive ingredients FD&amp;C Blue No. 2, hypromellose, lactose monohydrate, titanium dioxide, and triacetin. The tablets are imprinted with black ink containing the inactive ingredients ammonium hydroxide, ferrosoferric oxide, isopropyl alcohol, n-butyl alcohol, propylene glycol, and shellac glaze.</paragraph>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e3c29d4d-d2d2-435f-b719-f6836d48a349">
               <id root="3633492b-6102-f316-e063-6394a90a21d1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250109"/>
               <component>
                  <section ID="LINK_aabbee0a-576d-4b3c-af1e-fb2e91d6b850">
                     <id root="3633492b-6103-f316-e063-6394a90a21d1"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Mitapivat is a pyruvate kinase activator that acts by allosterically binding to the pyruvate kinase tetramer and increasing pyruvate kinase (PK) activity. The red blood cell (RBC) form of pyruvate kinase (PK-R) is mutated in PK deficiency, which leads to reduced adenosine triphosphate (ATP), shortened RBC lifespan, and chronic hemolysis.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ae690d18-a641-43e8-918f-987f9199bdc9">
                     <id root="3633492b-6104-f316-e063-6394a90a21d1"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Mitapivat decreases 2,3 diphosphoglycerate (2,3-DPG) and increases ATP in healthy volunteers.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At a dose 6 times the maximum recommended dose, mitapivat did not prolong the QT interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c82d6099-4f83-4fb1-8e77-01cc8af9b7d7">
                     <id root="3633492b-6105-f316-e063-6394a90a21d1"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Mitapivat exposure increased in an approximately dose proportional manner over the clinically relevant dose range of 5 mg to 50 mg twice daily.</paragraph>
                        <paragraph>The population pharmacokinetic model simulated Cmax, Ctrough, AUC0-12 and accumulation ratio of mitapivat at recommended dosages are listed in the table below.</paragraph>
                        <table width="664px">
                           <caption>Table 5: Steady State Mitapivat Exposure at Recommended Dosages
  
   <sup>a</sup>
                           </caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Mitapivat Dosage</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(ng/mL)</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">C</content>
                                       <content styleCode="bold">
                                          <sub>trough</sub>
                                          <br/>
                                       </content>
                                       <content styleCode="bold">(ng/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">AUC</content>
                                       <content styleCode="bold">
                                          <sub>0-12</sub>
                                          <br/>
                                       </content>
                                       <content styleCode="bold">(ng*h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Accumulation Ratio</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5 mg twice daily</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 101.2 (17%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 10.1 (74%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 450.4 (28%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 1.2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">20 mg twice daily</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 389.9 (18%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 32.3 (77%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 1623.8 (28%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 1.1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">50 mg twice daily</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 935.2 (18%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 62.1 (80%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 3591.4 (28%)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 1.0</td>
                              </tr>
                              <tr>
                                 <td colspan="5">
                                    <sup>a</sup>Pharmacokinetic parameters are presented as geometric mean (CV%). The simulations were performed until 100 days after first dose. The interval of the last 12 hours was selected for steady state PK parameters calculation. 
     <br/>  Residual error was not included during simulation.
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Median t
 
  <sub>max</sub>values at steady state were 0.5 to 1.0 hour post-dose across the dose range of 5 mg to 50 mg twice daily.

 </paragraph>
                        <paragraph>The absolute bioavailability after a single dose was approximately 73%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Effect of Food</content>
                        </paragraph>
                        <paragraph>Following administration of a single dose of PYRUKYND in healthy subjects, a high-fat meal (approximately 900 to 1,000 total calories, with 500 to 600 calories from fat, 250 calories from carbohydrate, and 150 calories from protein) did not change the exposure (AUC
 
  <sub>inf</sub>) of mitapivat, but reduced the rate of mitapivat absorption, with a 42% reduction in C
 
  <sub>max</sub>and a delay in t
 
  <sub>max</sub>of 2.3 hours when compared to dosing under fasted conditions.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Mitapivat is highly protein bound (97.7%) in plasma with low RBC distribution (RBC-to-plasma ratio of 0.37). The mean volume of distribution at steady state (Vss) was 42.5 L.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The mean effective half-life (t1/2) of mitapivat ranged from 3 to 5 hours following multiple dose administrations of 5 mg twice daily to 20 mg twice daily in patients with PK deficiency.</paragraph>
                        <paragraph>Population pharmacokinetics derived median CL/F at steady state was 11.5, 12.7, and 14.4 L/h for the 5 mg twice daily, 20 mg twice daily, and 50 mg twice daily regimens, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>studies showed that mitapivat is primarily metabolized by CYP3A4. Following a single oral dose of 120 mg of radiolabeled mitapivat to healthy subjects, unchanged mitapivat was the major circulating component.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Excretion</content>
                           </content>
                        </paragraph>
                        <paragraph>After a single oral administration of radiolabeled mitapivat to healthy subjects, the total recovery of administered radioactive dose was 89.2%, with 49.6% in the urine (2.6% unchanged) and 39.6% in the feces (&lt;1% unchanged).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically meaningful effects on the pharmacokinetics of mitapivat were observed based on age, sex, race, or body weight.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Pediatric Population</content>
                           </content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of mitapivat in children and adolescents (Ë18 years old) have not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Hepatic Impairment</content>
                           </content>
                        </paragraph>
                        <paragraph>Mitapivat undergoes extensive hepatic metabolism. Moderate and severe hepatic impairment is expected to increase the systemic exposure of mitapivat. The pharmacokinetics of mitapivat in patients with hepatic impairment have not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Renal Impairment</content>
                           </content>
                        </paragraph>
                        <paragraph>The effects of renal impairment on mitapivat pharmacokinetics were assessed with population pharmacokinetic analyses. Steady state AUC of mitapivat in patients with eGFR 60 to &lt;90 mL/min/1.73 m
 
  <sup>2</sup>was not significantly different compared to patients with eGFR â¥90 mL/min/1.73 m
 
  <sup>2</sup>. There are limited data available in patients with eGFR 30 to &lt;60 mL/min/1.73 m
 
  <sup>2</sup>and no data available in patients with eGFR &lt;30 mL/min/1.73 m
 
  <sup>2</sup>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Clinical Studies and Model-Based Approaches</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Strong CYP3A Inhibitors on PYRUKYND</content>
                        </paragraph>
                        <paragraph>Itraconazole (a strong CYP3A inhibitor) increased mitapivat AUCinf and Cmax by 4.9-fold and 1.7-fold, respectively, following a single PYRUKYND dose of 20 mg. Itraconazole increased mitapivat AUC
 
  <sub>0-12</sub>and C
 
  <sub>max</sub>by 3.6-fold and 2.2-fold, respectively, following PYRUKYND 50 mg twice daily. Ketoconazole (a strong CYP3A inhibitor) increased mitapivat AUC
 
  <sub>0-12</sub>and C
 
  <sub>max</sub>by approximately 3.9-fold and 2.4-fold, respectively, following PYRUKYND doses of 5, 20 or 50 mg twice daily.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Moderate CYP3A Inhibitors on PYRUKYND</content>
                        </paragraph>
                        <paragraph>Fluconazole (a moderate CYP3A inhibitor) increased mitapivat AUC0-12 and Cmax by approximately 2.6-fold and 1.6-fold, respectively, following PYRUKYND doses of 5, 20 or 50 mg twice daily.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Strong CYP3A Inducers on PYRUKYND</content>
                        </paragraph>
                        <paragraph>Rifampin (a strong CYP3A inducer) decreased mitapivat AUC
 
  <sub>inf</sub>and C
 
  <sub>max</sub>by 91% and 77%, respectively, following a single PYRUKYND dose of 50 mg. Rifampin decreased mitapivat AUC
 
  <sub>0-12</sub>and C
 
  <sub>max</sub>by approximately 95% and 85%, respectively, following PYRUKYND doses of 5, 20 or 50 mg twice daily.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Moderate CYP3A Inducers on PYRUKYND</content>
                        </paragraph>
                        <paragraph>Efavirenz (a moderate CYP3A4 inducer) decreased mitapivat AUC
 
  <sub>0-12</sub>and C
 
  <sub>max</sub>by approximately 60% and 30%, respectively, following PYRUKYND doses of 5 or 20 mg twice daily. Efavirenz decreased mitapivat AUC
 
  <sub>0-12</sub>and C
 
  <sub>max</sub>by 55% and 24%, respectively, following PYRUKYND doses of 50 mg twice daily.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of PYRUKYND on CYP3A substrates</content>
                        </paragraph>
                        <paragraph>Midazolam (a CYP3A substrate) AUC
 
  <sub>inf</sub>and C
 
  <sub>max</sub>decreased by 21% and 19%, respectively, following co-administration of midazolam with PYRUKYND 5 mg twice daily. Midazolam AUC
 
  <sub>inf</sub>and C
 
  <sub>max</sub>decreased by 43% and 39%, respectively, following co-administration with PYRUKYND 20 mg twice daily, and 57% and 52%, respectively, with PYRUKYND 50 mg twice daily.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of PYRUKYND on P-gp Substrates</content>
                        </paragraph>
                        <paragraph>Co-administration of PYRUKYND with drugs that are substrates of P-gp may result in a clinically relevant increase in plasma concentrations of these substrates.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">In vitro Studies</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">CYP450 and UGT Enzymes</content>
                        </paragraph>
                        <paragraph>Mitapivat induces CYP2B6, CYP2C8, CYP2C9, CYP2C19, and UGT1A1.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Drug Transporter Systems</content>
                        </paragraph>
                        <paragraph>Mitapivat is a substrate and an inhibitor of P-gp.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8e0ff5fd-5819-4d7a-b477-3aba7913c6ac">
               <id root="3633492b-6106-f316-e063-6394a90a21d1"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250109"/>
               <component>
                  <section ID="LINK_a6065dd2-808a-4339-b833-1ef9d3349ff9">
                     <id root="3633492b-6107-f316-e063-6394a90a21d1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Mitapivat was not carcinogenic in transgenic rasH2 mice up to the highest doses tested at 500 mg/kg/day in males and at 250 mg/kg/day in females when given orally for 26 weeks.</paragraph>
                        <paragraph>Mitapivat was not carcinogenic in rats when given orally up to 300 mg/kg/day in males and 200 mg/kg/day in females, at systemic exposures 47 times and &gt;100 times the MRHD, respectively, based on AUC.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Mitapivat was not mutagenic in an
 
  <content styleCode="italics">in vitro</content>bacterial reverse mutation (Ames) assay. Mitapivat was not clastogenic in an
 
  <content styleCode="italics">in vitro</content>human lymphocyte micronucleus assay or in an
 
  <content styleCode="italics">in vivo</content>rat bone marrow micronucleus assay.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Fertility</content>
                        </paragraph>
                        <paragraph>In a fertility and early embryonic development study, oral administration of mitapivat twice daily in male rats prior to and during mating at doses up to 300 mg/kg/day, which represents 45 times the MRHD of 50 mg twice daily, based on AUC, did not result in adverse effects on fertility or reproductive function. In female rats, twice daily oral administration of mitapivat prior to mating and continuing through organogenesis, at doses up to 200 mg/kg/day, which represents 48 times the MRHD of 50 mg twice daily, based on AUC, did not result in adverse effects on fertility or reproductive function.</paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3b95ac3a-e22f-442a-b814-8f94b19716d2">
               <id root="3633492b-6108-f316-e063-6394a90a21d1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Patients with PK Deficiency</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Patients Not Regularly Transfused</content>
                  </paragraph>
                  <paragraph>The efficacy of PYRUKYND was evaluated in ACTIVATE, a multinational, randomized, double-blind, placebo-controlled clinical study (NCT03548220) of 80 adults with PK deficiency who were not regularly transfused, defined as having had no more than 4 transfusions in the 52- week period prior to treatment and no transfusions in the 3-month period prior to treatment.</paragraph>
                  <paragraph>Patients were included if they had documented presence of at least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene, of which at least 1 was a missense variant, and Hb less than or equal to 10 g/dL. Patients who were homozygous for the c.1436G&gt;A (p.R479H) variant or had 2 non-missense variants (without the presence of another missense variant) in the PKLR gene were excluded because these patients did not achieve Hb response (change from baseline in Hb â¥1.5 g/dL at &gt;50% assessments) in the dose-ranging study.</paragraph>
                  <paragraph>Randomization was stratified by average screening Hb (&lt;8.5 vs â¥8.5 g/dL) and PKLR gene variant category (missense/missense vs. missense/non-missense).</paragraph>
                  <paragraph>Among the 80 patients with PK deficiency, 40 patients were randomized to PYRUKYND. Following a period of dose titration up to 50 mg twice daily, patients continued a fixed dose of PYRUKYND for 12 weeks. Eighty-eight percent of patients were maintained on 50 mg twice daily.</paragraph>
                  <paragraph>The median duration of treatment with PYRUKYND was 24.1 weeks (range 23.6 to 27.4 weeks). Overall, 30 (75%) patients were exposed to PYRUKYND for &gt;24 weeks and &lt;28 weeks. Among the 80 randomized patients, the median age was 33 years (range 18 to 78) and 40% were male; race was reported in 88% of patients: 75% were White, 10% Asian, 1.3% Native Hawaiian/Other Pacific Islander and 1.3% were other races. The median baseline hemoglobin was 8.5 g/dL (range: 6.4 to 10.2 g/dL). There were 55 patients (69%) with the missense/missense PKLR gene variant category, and 25 patients (31%) with the missense/non-missense PKLR gene variant category. There were 58 patients (73%) who had a history of splenectomy. Complications and comorbidities associated with PK deficiency included iron overload with a median baseline ferritin of 479 ng/mL (range: 21 to 5890 ng/mL), chelation therapy use in the year before the first dose of study treatment in 15 patients (19%), decreased bone mineral density in 64 patients (80%) who had a baseline femoral neck T-score or lumbar spine T-score &lt;-1.0, and history of cholecystectomy in 58 patients (73%).</paragraph>
                  <paragraph>Efficacy was based upon Hb response, defined as a â¥1.5 g/dL increase in Hb from baseline sustained at 2 or more scheduled assessments (Weeks 16, 20, and 24) during the fixed dose period without transfusions. The efficacy results, including changes in markers of hemolysis are shown in Table 6.</paragraph>
                  <table width="714px">
                     <caption>Table 6: Efficacy Results in Patients with PK Deficiency Who Were Not Regularly Transfused (ACTIVATE)</caption>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Endpoint</content>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">PYRUKYND 
      <br/>  N=40
     </content>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Placebo 
      <br/>  N=40
     </content>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Difference
     
      <sup>1,</sup>
                              </content>
                              <content styleCode="bold">
                                 <sup>2</sup>
                                 <br/>
                              </content>
                              <content styleCode="bold">p-value</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Hb Response, n (%)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 16 (40%)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 0</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 39 (24, 55) 
     <br/>  &lt;0.0001
    </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Hemoglobin (g/dL) 
     <br/>  Â  Â Baseline Mean (SD) 
     <br/>  Â  Â LS Mean Change (95% CI)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 8.6 (1.0) 
     <br/>  1.7 (1.3, 2.1)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">8.5 (0.8) 
     <br/>  -0.1 (-0.6, 0.3)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 1.8 (1.2, 2.4) 
     <br/>  &lt;0.0001
    </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Indirect bilirubin (mg/dL) 
     <br/>  Â  Â Baseline Mean (SD) 
     <br/>  Â  Â LS Mean Change (95% CI)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 4.8 (3.6) 
     <br/>  -1.2 (-1.7, -0.7)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 5.2 (3.6) 
     <br/>  0.3 (-0.2, 0.8)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â -1.5 (-2.2, -0.9) 
     <br/>  &lt;0.0001
    </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Reticulocyte 
     <br/>  (fraction of 1) 
     <br/>  Â  Â Baseline Mean (SD) 
     <br/>  Â  Â LS Mean Change (95% CI) 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 0.37 (0.24) 
     <br/>  -0.10 (-0.13, -0.07)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 0.40 (0.22) 
     <br/>  0 (-0.02, 0.03)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â -0.10 (-0.14, -0.06) 
     <br/>  &lt;0.0001
    </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule" valign="top">LDH (U/L) 
     <br/>  Â  Â Baseline Mean (SD) 
     <br/>  Â  Â LS Mean Change (95% CI) 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 348 (276) 
     <br/>  -92 (-124, -60)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 260 (140) 
     <br/>  -21 (-53, 11)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-71 (-116, -26) 
      <br/>  0.003
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Haptoglobin (mg/dL) 
     <br/>  Â  Â Baseline Mean (SD) 
     <br/>  Â  Â LS Mean Change (95% CI)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 8.2 (10.7) 
     <br/>  16.9 (8.8, 25.1)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 8.3 (13.8) 
     <br/>  1.2 (-7.0, 9.4)
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 15.8 (4.3, 27.3) 
     <br/>  0.008
    </td>
                        </tr>
                        <tr>
                           <td colspan="4">CI: confidence interval, Hb: hemoglobin, LDH: lactate dehydrogenase, LS Mean Change: least square mean change from baseline, SD: standard deviation
    
     <paragraph>
                                 <sup>1</sup>All results are statistically significant.
    
     </paragraph>
                              <paragraph>
                                 <sup>2</sup>For Hb response, the difference is adjusted for randomization stratification factors, which included average screening Hb (&lt;8.5, â¥8.5 g/dL) and PKLR gene variant category (missense/missense, missense/non-missense). The two-sided p-value is based on the Mantel-Haenszel stratum weighted method adjusting for the randomization stratification factors.
    
     </paragraph>For the endpoints of average change from baseline at Weeks 16, 20, and 24 for hemoglobin, indirect bilirubin, reticulocytes, LDH, and haptoglobin, the two-sided p-value is based on the mixed-effect model repeat measurement (MMRM) method, which included change from baseline as the dependent variable, baseline as a covariate, and treatment arm, visit, treatment-by-visit interaction, and the randomization stratification factors as fixed factors and subject as the random effect. All scheduled visits were included in the model.
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>In ACTIVATE, the LS Mean change from baseline with PYRUKYND compared to placebo was -0.4 (standard error [SE] 0.1) for jaundice (scale: 0-4), -1.1 (SE 0.4) for tiredness (scale: 0-10), and -0.3 (SE 0.3) for shortness of breath (scale: 0-10), assessed with the daily Pyruvate Kinase Deficiency Diary (PKDD) where lower scores represent less sign/symptom severity.</paragraph>
                  <paragraph>In ACTIVATE, the majority of PYRUKYND-treated patients experienced an increase in Hb, while the majority of patients in the placebo arm experienced a decrease in Hb as measured by average change from baseline at weeks 16, 20, and 24 (Figure 1).</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>
                     <sup>aÂ </sup>Approximately 99% of all randomized patients completed 24 weeks of treatment.

 </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>CI: confidence interval, Hb: hemoglobin, LS: least square</paragraph>
                  <paragraph>Fifteen of the 16 patients with a Hb response in ACTIVATE continued in a long-term extension study and were evaluable for maintenance of response. Thirteen maintained increases in Hb concentration from baseline above the response threshold of â¥1.5 g/dL at the last available Hb assessment without requiring any transfusions. The median duration of response for the 16 patients with Hb response was 6.9 months (range: 3.3, 18.4+).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Patients Who Were Regularly Transfused</content>
                  </paragraph>
                  <paragraph>The efficacy of PYRUKYND in patients with PK deficiency who were regularly transfused was evaluated in ACTIVATE-T, a multinational single-arm clinical trial (NCT03559699) of 27 adults with PK deficiency who had a minimum of 6 transfusion episodes in the 52-week period prior to informed consent. Patients were included if they had documented presence of at least 2 variant alleles in the PKLR gene, of which at least 1 was a missense variant. Patients who were homozygous for the c.1436G&gt;A (p.R479H) variant or had 2 non-missense variants (without the presence of another missense variant) in the PKLR gene were excluded. Following a period of dose titration up to 50 mg twice daily, patients continued on a fixed dose of PYRUKYND for 24 weeks.</paragraph>
                  <paragraph>The median duration of treatment with PYRUKYND was 40.3 weeks (range 16.3 to 46.3 weeks). Overall, 20 (74%) patients were exposed to PYRUKYND for &gt;40 weeks and &lt;47 weeks. The median age was 36 years (range 18 to 68) and 26% were male; race was reported in 85% of patients: 74% were White and 11% Asian. The median baseline hemoglobin was 9.1 g/dL (range: 7.4 to 10.9 g/dL). Patients had a median of 9 transfusion episodes (range: 6 to 17 episodes) in the 52 weeks before the first dose of study treatment and a median of 7 red blood cell units transfused (range: 3 to 20 units) standardized to 24 weeks. There were 20 patients (74%) with the missense/missense PKLR gene variant category, and 7 patients (26%) with the missense/non-missense PKLR gene variant category. There were 21 patients (78%) who had a history of splenectomy. Patients had evidence of complications and comorbidities associated with PK deficiency including iron overload (median baseline ferritin was 1324 ug/L; range: 163 to 5357 ng/mL), chelation therapy use in the year before the first dose of study treatment in 24 patients (89%), decreased bone mineral density in 20 patients (74%) who had a baseline femoral neck T-score or lumbar spine T-score &lt;-1.0, and history of cholecystectomy in 23 patients (85%).</paragraph>
                  <paragraph>Efficacy was based on transfusion reduction response and was defined as â¥33% reduction in the number of red blood cell (RBC) units transfused during the fixed dose period compared with the patientâs historical transfusion burden.</paragraph>
                  <paragraph>Efficacy results for patients with PK deficiency who were regularly transfused are presented in Table 7.</paragraph>
                  <table width="540px">
                     <caption>Table 7: Efficacy Results in Patients with PK Deficiency Who Were Regularly Transfused (ACTIVATE-T)</caption>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Endpoints</content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">PYRUKYND 
      <br/>  N=27
     </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Patients with Transfusion Reduction Response 
       <br/>  Â  Â  Â 
      </content>n (%) 
      <br/>  Â  Â  Â 95% CI
    
     </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <br/>  9 (33) 
     <br/>  (17, 54)
    </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Patients who were Transfusion Free 
      <br/>  Â  Â  Â 
     </content>n (%) 
     <br/>  Â  Â  Â 95% CI
   
    </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  
     <br/>  6 (22) 
     <br/>  (9, 42)
    </td>
                        </tr>
                        <tr>
                           <td colspan="2">CI: confidence interval, RBC: red blood cell CI is based on Clopper-Pearson method.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>All 6 (22%) patients who were transfusion free in ACTIVATE-T remained transfusion free in a long-term extension study. The median duration of response for the 6 patients was 17 months (range: 11.5+, 21.8+).</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_792f24e2-c6b8-4eae-bf5e-8e7b1e6f7a7c">
               <id root="3633492b-6109-f316-e063-6394a90a21d1"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Â </content>
                     <content styleCode="bold">How Supplied</content>
                  </paragraph>
                  <table width="781px">
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="4" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">
                                 <content styleCode="underline">PYRUKYND 28-Day Packs</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Tablet Strength</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Description</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Imprint</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">NDC</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">5 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â Round, blue, film-coated tablets</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â "M5" printed on one side</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 71334-205-05</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">20 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â Round, blue, film-coated tablets</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â "M20" printed on one side</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 71334-210-20</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">50 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â Oblong, blue, film-coated tablets</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â "M50" printed on one side</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 71334-215-50</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="889px" cellspacing="0">
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="5" styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">
                                 <content styleCode="underline">PYRUKYND Taper Packs</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Tablet strength(s)</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Blister Wallet Configuration</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Tablet Description</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">Imprint</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <content styleCode="bold">NDC</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">5 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 5 mg blister wallet containing 7 tablets</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â round, blue, film-coated tablets</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">"M5" printed on one side 
     <br/>
                              <br/>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">71334-220-11</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>20 mg and 5 mg</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
    
     <list listType="unordered">
                                 <item>20 mg blister wallet containing 7 tablets</item>
                                 <item>5 mg blister wallet containing 7 tablets</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <br/>  round, blue, film-coated tablets 
     <br/>  round, blue, film-coated tablets
    </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">"M20" 
     <br/>  printed on one side 
     <br/>  "M5" printed on one side
    </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">71334-225-12</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">50 mg and 20 mg</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <list listType="unordered">
                                 <item>50 mg blister wallet containing 7 tablets</item>
                                 <item>20 mg blister wallet containing 7 tablets</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">oblong, blue, film- coated tablets 
     <br/>  round, blue, film-coated tablets
    </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>"M50"</paragraph>printed on one side 
     <br/>
                              <paragraph>"M20"</paragraph>printed on one side
   
    </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">71334-230-13</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Â </content>Store at 20Â°C to 25Â°C (68Â°F to 77Â°F) with excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F)
 
  <content styleCode="italics">[see USP Controlled Room Temperature]</content>. Store the blister wallets in the original carton until use.

 </paragraph>
               </text>
               <effectiveTime value="20250109"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b4e7c5f1-d326-4d38-9547-1116f32c6213">
               <id root="3633492b-610a-f316-e063-6394a90a21d1"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Acute Hemolysis with Abrupt Treatment Interruption</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk of developing acute hemolysis and subsequent anemia following abrupt interruption or discontinuation of PYRUKYND. Inform patients to follow their healthcare providerâs instructions for discontinuing PYRUKYND. Upon discontinuing PYRUKYND, tell patients to immediately report any symptoms suggestive of acute hemolysis including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath to their healthcare provider for further evaluation
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_a4c74e6f-f2ba-4af6-b6f2-2764e2a7c13f">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatocellular Injury in Another Condition</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk of hepatocellular injury observed in patients with another condition during the first 6 months of treatment with PYRUKYND at a higher dose than that recommended for patients with PK deficiency. Tell patients to immediately report any symptoms suggestive of liver injury including jaundice, dark urine, right upper quadrant pain, nausea, vomiting, or loss of appetite to their healthcare provider for further evaluation
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_bd3c824d-ed74-4150-83c5-482dac1c8ed4">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications, vitamins, and herbal products
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_5984e014-3642-4eda-ad9f-4222d98a149c">Drug Interactions (7)</linkHtml>].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosing and Storage Instructions</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Instruct patients to swallow the tablets whole with or without food and not to split, crush, chew, or dissolve the tablets.</item>
                     <item>Advise patients if a dose of PYRUKYND is missed by 4 hours or less, to take the scheduled dose as soon as possible. If a dose of PYRUKYND is missed by more than 4 hours, advise the patient to not take a replacement dose and wait until the next scheduled dose.</item>
                  </list>
                  <paragraph>PYRUKYND
 
  <sup>Â®</sup>is a registered trademark of Agios Pharmaceuticals, Inc.

 </paragraph>
                  <paragraph>Â© 2022 Agios Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Manufactured for and Distributed by:</paragraph>
                  <paragraph>Agios Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Cambridge, MA 02139</paragraph>
                  <paragraph>AG-PI-002</paragraph>
               </text>
               <effectiveTime value="20250109"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4bd62af6-294f-44cb-9708-39b81c21d549">
               <id root="3633492b-610b-f316-e063-6394a90a21d1"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table width="850px">
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION 
       <br/>
                                 </content>
                                 <content styleCode="bold">PYRUKYND [</content>
                                 <content styleCode="bold">pye rooâ kind</content>
                                 <content styleCode="bold">] 
       <br/>
                                 </content>
                                 <content styleCode="bold">(mitapivat) 
       <br/>
                                 </content>
                                 <content styleCode="bold">tablets, for oral use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is PYRUKYND?</content>
                              </paragraph>
                              <paragraph>PYRUKYND is a prescription medicine used to treat low red blood cell counts caused by the early breakdown of red blood cells (hemolytic anemia) in adults with pyruvate kinase deficiency (PK Deficiency).</paragraph>It is not known if PYRUKYND is safe and effective in children.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before taking PYRUKYND, tell your healthcare provider about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have liver problems.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if PYRUKYND will harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with PYRUKYND.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if PYRUKYND passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with PYRUKYND.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines that you take</content>, including prescription and over-the- counter medicines, vitamins, and herbal supplements.
    
     </paragraph>
                              <paragraph>PYRUKYND and certain other medicines may affect each other causing side effects. PYRUKYND may affect the way other medicines work, and other medicines may affect how PYRUKYND works.</paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I take PYRUKYND?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take PYRUKYND exactly as your healthcare provider tells you to take it.</item>
                                 <item>Take PYRUKYND with or without food.</item>
                                 <item>Swallow PYRUKYND tablets whole. Do not split, chew, crush, or dissolve the tablets.</item>
                                 <item>Do not change your dose or stop taking PYRUKYND without talking to your healthcare provider. Your healthcare provider will give you instructions for stopping PYRUKYND. See
      
       <content styleCode="bold">âWhat are the possible side effects of PYRUKYND?â</content>
                                 </item>
                                 <item>If you miss a dose of PYRUKYND by 4 hours or less, take your dose as soon as possible. If more than 4 hours have passed since your regularly scheduled dose, wait for the next dose. Return to your normal schedule at the next dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of PYRUKYND? PYRUKYND may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Rapid breakdown of red blood cells (acute hemolysis)</content>has happened after suddenly interrupting or stopping treatment with PYRUKYND.
      
       <content styleCode="bold">You should not suddenly stop taking PYRUKYND.</content>If you have to stop your treatment with PYRUKYND, your healthcare provider should monitor you closely. Tell your healthcare provider right away if you develop any signs or symptoms of breakdown of red blood cells including:
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>yellowing of your skin or the whites of your eyes (jaundice)</item>
                                 <item>dark colored urine</item>
                                 <item>dizziness</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>feeling tired</item>
                                 <item>shortness of breath</item>
                                 <item>confusion</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Liver injury</content>has happened in people with another condition during the first 6 months of treatment with PYRUKYND when given at a dose higher than recommended for people with PK deficiency. Your healthcare provider will do blood tests to check your liver before you start treatment with PYRUKYND, monthly for the first 6 months of treatment, and as needed. Your healthcare provider may temporarily or permanently stop your treatment with PYRUKYND if you have abnormal liver tests. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems including:
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>yellowing of your skin or the whites of your eyes (jaundice)</item>
                                 <item>dark colored urine</item>
                                 <item>pain in the upper right side of your stomach area</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nausea</item>
                                 <item>vomiting</item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <content styleCode="bold">The most common side effects of PYRUKYND include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered">
                                 <item>decrease in reproductive hormone (estrone) in men</item>
                                 <item>increased salt from uric acid (urate) blood test</item>
                                 <item>back pain</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">
                              <list listType="unordered">
                                 <item>decrease in reproductive hormone (estradiol) in men</item>
                                 <item>joint pain (arthralgia)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Lrule Rrule">
                              <paragraph>These are not all of the possible side effects of PYRUKYND.</paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store PYRUKYND?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store PYRUKYND at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                                 <item>Store the blister wallets in the original carton until use.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">Keep PYRUKYND and all medicines out of the reach of children.</content>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of PYRUKYND.</content>
                              </paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PYRUKYND for a condition for which it was not prescribed. Do not give PYRUKYND to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about PYRUKYND that is written for healthcare professionals.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in PYRUKYND?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content>mitapivat
    
     </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content>croscarmellose sodium, mannitol, microcrystalline cellulose, and sodium stearyl fumarate.
    
     </paragraph>
                              <paragraph>The tablet film coating contains: FD&amp;C Blue No. 2, hypromellose, lactose monohydrate, titanium dioxide, and triacetin.</paragraph>
                              <paragraph>The tablets printed with black ink contains: ammonium hydroxide, ferrosoferric oxide, isopropyl alcohol, n-butyl alcohol, propylene glycol, and shellac glaze.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Manufactured for and Distributed by</content>:
    
     </paragraph>
                              <paragraph>Agios Pharmaceuticals, Inc.</paragraph>
                              <paragraph>Cambridge, MA 02139</paragraph>
                              <paragraph>PYRUKYNDÂ® is a trademark of Agios Pharmaceuticals, Inc. 
      <br/>  Â© 2022 Agios Pharmaceuticals, Inc. All rights reserved. 
      <br/>  For more information, visit www.pyrukynd.com or call 1-833-228-8474
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2">This Patient Information has been approved by the U.S. Food and Drug Administration.Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Revised: 1/2025</td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20250109"/>
            </section>
         </component>
         <component>
            <section ID="LINK_29457f43-820d-4273-bc5e-825ed68b9a6f">
               <id root="3633492b-610c-f316-e063-6394a90a21d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg Tablet Blister Pack Carton</title>
               <text>
                  <paragraph>NDC 71334-205-05 
  <br/>  Do not use if seal 
  <br/>  is broken or damaged
 </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>pyrukyndÂ Â® 
  <br/>  (mitapivat) tablets 
  <br/>  5 mg per tablet
 </paragraph>
                  <paragraph>56 tablets</paragraph>
                  <paragraph>Contains 4-week supply of PYRUKYNDÂ Â® 
  <br/>  (Four 7-day blister wallets with 14 tablets per wallet) 
  <br/>  Swallow tablets whole. Do Not split, crush, chew, or dissolve the tablets.
 </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>5 mg Blister Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_69675596-0e26-45ed-89eb-4fe8a3b3a5db">
               <id root="3633492b-610d-f316-e063-6394a90a21d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 20 mg Tablet Blister Pack Carton</title>
               <text>
                  <paragraph>NDC 71334-210-20 
  <br/>  Do not use if seal 
  <br/>  is broken or damaged
 </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>pyrukyndÂ Â® 
  <br/>  (mitapivat) tablets 
  <br/>  20 mg per tablet
 </paragraph>
                  <paragraph>56 tablets</paragraph>
                  <paragraph>Contains 4-week supply of PYRUKYNDÂ Â® 
  <br/>  (Four 7-day blister wallets with 14 tablets per wallet) 
  <br/>  Swallow tablets whole. Do Not split, crush, chew, or dissolve the tablets.
 </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>20 mg Blister Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1c3a4240-8ab5-4baa-bf88-fb7f3eea3012">
               <id root="3633492b-610e-f316-e063-6394a90a21d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 50 mg Tablet Blister Pack Carton</title>
               <text>
                  <paragraph>NDC 71334-215-50 
  <br/>  Do not use if seal 
  <br/>  is broken or damaged
 </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>pyrukyndÂ Â® 
  <br/>  (mitapivat) tablets 
  <br/>  50 mg per tablet
 </paragraph>
                  <paragraph>56 tablets</paragraph>
                  <paragraph>Contains 4-week supply of PYRUKYNDÂ Â® 
  <br/>  (Four 7-day blister wallets with 14 tablets per wallet) 
  <br/>  Swallow tablets whole. Do Not split, crush, chew, or dissolve the tablets.
 </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <br/>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>50 mg Blister Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_fd981398-79d8-48fa-b988-de59323352d7">
               <id root="3633492b-610f-f316-e063-6394a90a21d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg Tablet Blister Pack Carton - 220-11</title>
               <text>
                  <paragraph>NDC 71334-220-11 
  <br/>  Do not use if seal is broken or damaged
 </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>pyrukyndÂ Â® 
  <br/>  (mitapivat) tablets
 </paragraph>
                  <paragraph>Week 1 
  <br/>  5 mg per tablet
 </paragraph>
                  <paragraph>5 mg TAPER PACK</paragraph>
                  <paragraph>7 tablets</paragraph>
                  <paragraph>Swallow tablets whole. 
  <br/>  Do Not split, crush, chew, or dissolve the tablets.
 </paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>5 mg Taper Pack</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_641fc9a6-cc4a-4ae4-af6b-63c965ee33fa">
               <id root="3633492b-6110-f316-e063-6394a90a21d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 20 mg/5 mg Tablet Blister Pack Carton - 225-12</title>
               <text>
                  <paragraph>NDC 71334-225-12 
  <br/>  Do not use if seal is broken or damaged
 </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>pyrukyndÂ Â® 
  <br/>  (mitapivat) tablets
 </paragraph>
                  <paragraph>Week 1 
  <br/>  20 mg per tablet
 </paragraph>
                  <paragraph>Week 2 
  <br/>  5 mg per tablet
 </paragraph>
                  <paragraph>20 mg and 5 mg TAPER PACK</paragraph>
                  <paragraph>14 tablets</paragraph>
                  <paragraph>Contains two 7-day blister wallets with 7 tablets per wallet: 
  <br/>  7 film-coated tablets of 20 mg per tablet (one tablet per day during week 1) 
  <br/>  7 film-coated tablets of 5 mg per tablet (one tablet per day during week 2)
 </paragraph>
                  <paragraph>Swallow tablets whole. 
  <br/>  Do Not split, crush, chew, or dissolve the tablets.
 </paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>20 mg and 5 mg Taper Pack</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ae795b65-f5cf-4f80-8559-a7a758935a29">
               <id root="3633492b-6111-f316-e063-6394a90a21d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 50 mg/20 mg Tablet Blister Pack Carton - 230-13</title>
               <text>
                  <paragraph>NDC 71334-230-13 
  <br/>  Do not use if seal is broken or damaged
 </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>pyrukyndÂ Â® 
  <br/>  (mitapivat) tablets
 </paragraph>
                  <paragraph>Week 1 
  <br/>  50 mg per tablet
 </paragraph>
                  <paragraph>Week 2 
  <br/>  20 mg per tablet
 </paragraph>
                  <paragraph>50 mg and 20 mg TAPER PACK</paragraph>
                  <paragraph>14 tablets</paragraph>
                  <paragraph>Contains two 7-day blister wallets with 7 tablets per wallet: 
  <br/>  7 film-coated tablets of 50 mg per tablet (one tablet per day during week 1) 
  <br/>  7 film-coated tablets of 20 mg per tablet (one tablet per day during week 2)
 </paragraph>
                  <paragraph>Swallow tablets whole. 
  <br/>  Do Not split, crush, chew, or dissolve the tablets.
 </paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20250109"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>50 mg and 20 mg Taper Pack</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pyrukynd-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>